Papillary Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PPL018 MIFTS: 46	Papillary Adenocarcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma ¹² ¹⁵ ⁷¹

Infiltrating and Papillary Adenocarcinoma ¹²

Infiltrating Papillary Adenocarcinoma ¹²

Adenocarcinoma, Papillary ⁴³

Adenocarcinoma Papillary ⁵⁴

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3112

MeSH ⁴³ D000231

NCIt ⁴⁹ C2853 C7438

SNOMED-CT ⁶⁷ 4797003 64524002

UMLS ⁷¹ C0001420 C1321863

Sources

Summaries for Papillary Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to gastric papillary adenocarcinoma and eccrine papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are ERK Signaling and Pathways in cancer. The drugs Letrozole and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and lung, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Increased cell death HMECs cells

Wikipedia : ⁷⁴ Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Sources

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)

#	Related Disease	Score	Top Affiliating Genes
1	gastric papillary adenocarcinoma	34.9	TP53 ERBB2
2	eccrine papillary adenocarcinoma	33.9	PIP PGR KRT7 CEACAM5
3	papillary serous adenocarcinoma	31.4	TP53 PGR NKX2-1 MIR30A MIR141 KRT7
4	cervical adenocarcinoma	31.2	TP53 KRT7 ERBB2 CEACAM5
5	rete testis adenocarcinoma	31.1	NKX2-1 KRT7
6	adenoma	31.1	TP53 MUC1 KRT7 CDH1
7	adenocarcinoma	31.0	TP53 NKX2-1 MUC1 MST1R KRT7 ERBB2
8	thyroid carcinoma	31.0	TP53 NKX2-1 CDH1
9	papillary adenoma	30.8	VIM TP53 NKX2-1 KRT7
10	thyroid gland papillary carcinoma	30.6	NKX2-1 MIR30A KRT19
11	microinvasive gastric cancer	30.6	TP53 ERBB2 CEACAM5 CDH1
12	pseudo-meigs syndrome	30.5	MUC16 CDH1
13	eccrine papillary adenoma	30.5	PIP CEACAM5
14	cholecystitis	30.4	TP53 MUC1 CDH1
15	ureter adenocarcinoma	30.4	NKX2-1 KRT7 CEACAM5
16	glandular cystitis	30.4	TP53 MUC1 KRT7
17	papillary carcinoma	30.4	PGR NKX2-1 MUC1 KRT7 KRT19 ERBB2
18	thymoma	30.4	TP53 NKX2-1 MUC1 KRT7
19	myoma	30.3	PGR MUC16 CEACAM5
20	ovarian brenner tumor	30.3	MUC16 KRT7
21	bronchiolo-alveolar adenocarcinoma	30.3	NKX2-1 KRT7 CEACAM5 CDH1
22	appendix adenocarcinoma	30.3	KRT7 CEACAM5
23	tubular adenocarcinoma	30.3	PGR MUC1 KRT7 ERBB2 CEACAM5 CDH1
24	benign mesothelioma	30.3	KRT7 CEACAM5
25	sclerosing hemangioma	30.2	PGR NKX2-1 MUC1 KRT7
26	spiradenoma	30.2	VIM TP53 MUC1 KRT7
27	epithelial-myoepithelial carcinoma	30.2	VIM TP53 MUC1 KRT7
28	myoepithelial carcinoma	30.2	VIM TP53 MUC1 KRT7
29	endometrial adenocarcinoma	30.2	VIM TP53 PGR MUC1 KRT7 ERBB2
30	hemangioma	30.2	TP53 PGR NKX2-1 MUC1 KRT7
31	peritoneal mesothelioma	30.2	PGR MUC16 MUC1 CEACAM5
32	hidradenoma	30.2	VIM PIP MUC1 KRT7 CEACAM5
33	sweat gland neoplasm	30.2	TP53 PIP KRT7 ERBB2 CEACAM5
34	cystadenoma	30.2	PGR MUC16 MUC1 KRT7 CEACAM5 BRCA1
35	follicular adenoma	30.1	NKX2-1 KRT19 CDH1
36	cystitis	30.1	VIM TP53 KRT7 CDH1
37	hidrocystoma	30.0	PIP KRT7 KRT19 CEACAM5
38	eccrine sweat gland neoplasm	30.0	PIP KRT7 KRT19 CEACAM5
39	oncocytoma	30.0	VIM NKX2-1 MUC1 KRT7 KRT19
40	barrett esophagus	30.0	TP53 KRT7 ERBB2 CDH1
41	transitional cell carcinoma	30.0	TP53 KRT7 KRT19 ERBB2 CDH1
42	fallopian tube carcinoma	30.0	TP53 PGR ERBB2 BRCA2 BRCA1
43	endosalpingiosis	29.8	TP53 PGR MUC1 KRT7 BRCA2 BRCA1
44	serous cystadenocarcinoma	29.8	TP53 PGR MUC16 MIR30A ERBB2 BRCA2
45	squamous cell carcinoma	29.8	TP53 NFE2L2 MUC1 KRT19 ERBB2 CEACAM5
46	gallbladder cancer	29.8	TP53 MUC1 KRT7 KRT19 ERBB2 CEACAM5
47	endocervical adenocarcinoma	29.8	VIM TP53 PGR MUC1 KRT7 CEACAM5
48	primary peritoneal carcinoma	29.8	TP53 PGR MUC16 ERBB2 BRCA2 BRCA1
49	basal cell carcinoma	29.7	TP53 KRT7 KRT19 CEACAM5 CDH1
50	thymic carcinoma	29.7	TP53 NKX2-1 MUC1 KRT7 KRT19 CEACAM5

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:

Sources

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.35	CDH2 ERBB2 MST1R MUC1 VIM
2	Increased cell death HMECs cells	GR00103-A-0	9.1	BRCA1 KEAP1 MST1R PGR PIP TP53

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.31	BRCA1 BRCA2 CDH1 CDH2 ERBB2 KRT19
2	cardiovascular system	MP:0005385	10.25	BRCA1 CDH1 CDH2 ERBB2 KRT19 NFE2L2
3	homeostasis/metabolism	MP:0005376	10.22	BRCA1 BRCA2 CDH1 CDH2 ERBB2 KEAP1
4	digestive/alimentary	MP:0005381	10.18	BRCA1 BRCA2 CDH1 ERBB2 KEAP1 KRT19
5	embryo	MP:0005380	10.16	BRCA1 BRCA2 CDH1 CDH2 ERBB2 KRT19
6	endocrine/exocrine gland	MP:0005379	10.13	BRCA1 BRCA2 CDH1 ERBB2 KRT19 MST1R
7	mortality/aging	MP:0010768	10.13	BRCA1 BRCA2 CDH1 CDH2 ERBB2 KEAP1
8	integument	MP:0010771	10.02	BRCA1 BRCA2 CDH1 ERBB2 KEAP1 KRT19
9	neoplasm	MP:0002006	9.91	BRCA1 BRCA2 CDH1 ERBB2 KRT19 NFE2L2
10	normal	MP:0002873	9.81	BRCA1 BRCA2 CDH1 ERBB2 KRT19 NFE2L2
11	reproductive system	MP:0005389	9.7	BRCA1 BRCA2 CDH1 ERBB2 KRT19 MST1R
12	respiratory system	MP:0005388	9.23	BRCA1 ERBB2 KEAP1 KRT19 NFE2L2 NKX2-1

Sources

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030 46835353

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Everolimus

Approved

Phase 2

159351-69-6

6442177 70789204

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Romidepsin

Approved, Investigational

Phase 2

128517-07-7

5352062

Azacitidine

Approved, Investigational

Phase 2

320-67-2

9444

Decitabine

Approved, Investigational

Phase 2

2353-33-5

451668

Ipilimumab

Approved

Phase 2

477202-00-9

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Pembrolizumab

Approved

Phase 2

1374853-91-4

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Olaparib

Approved

Phase 1, Phase 2

763113-22-0

23725625

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

Sunitinib

Approved, Investigational

Phase 2

341031-54-7, 557795-19-4

5329102

Trametinib

Approved

Phase 2

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760 44516822

Salmon Calcitonin

Approved, Investigational

Phase 2

47931-85-1

16129616

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Lenalidomide

Approved

Phase 1, Phase 2

191732-72-6

216326

nivolumab

Approved

Phase 2

946414-94-4

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Tyrosine

Approved, Investigational, Nutraceutical

Phase 2

60-18-4

6057

Tremelimumab

Investigational

Phase 2

745013-59-6

MK-1775

Investigational

Phase 2

955365-80-7, 501-36-0

24856436 445154

Cediranib

Investigational

Phase 1, Phase 2

288383-20-0

9933475

Maleic acid

Experimental, Investigational

Phase 1, Phase 2

110-17-8, 110-16-7

444972

Calcitonin gene-related peptide

Investigational

Phase 2

83652-28-2

Atrasentan

Investigational

Phase 2

173937-91-2, 195733-43-8

159594

Estrogens

Phase 2

Aromatase Inhibitors

Phase 2

Estrogen Receptor Antagonists

Phase 2

Estrogen Antagonists

Phase 2

Steroid Synthesis Inhibitors

Phase 2

Hormones

Phase 2

Antifungal Agents

Phase 2

Liver Extracts

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Immunoglobulin G

Phase 2

Radiopharmaceuticals

Phase 2

Fluorodeoxyglucose F18

Phase 2

Fluorides

Phase 2

Deoxyglucose

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Immunoglobulins

Phase 2

Interventional clinical trials:

(show all 30)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas	Unknown status	NCT02283658	Phase 2	Everolimus;Letrozole
2	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
3	A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma	Completed	NCT00104871	Phase 2	Bortezomib
4	A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma	Completed	NCT00098813	Phase 2	romidepsin
5	Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine	Completed	NCT00085293	Phase 2	Decitabine
6	Sutent Adjunctive Treatment of Differentiated Thyroid Cancer	Completed	NCT00668811	Phase 2	SU011248, Sutent
7	Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy	Completed	NCT01811212	Phase 2	Cabozantinib S-malate
8	A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy	Completed	NCT00729157	Phase 2
9	A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors	Recruiting	NCT03037385	Phase 1, Phase 2	pralsetinib (BLU-667)
10	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
11	A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial	Recruiting	NCT03753919	Phase 2	Durvalumab;Tremelimumab
12	A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer	Recruiting	NCT03506048	Phase 2	Lenvatinib
13	Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy	Recruiting	NCT03914300	Phase 2	Cabozantinib;Cabozantinib S-malate
14	Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers	Recruiting	NCT02393690	Phase 2	Selumetinib
15	Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study	Recruiting	NCT02973997	Phase 2	Lenvatinib
16	A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers	Recruiting	NCT02152995	Phase 2	Trametinib
17	A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	Active, not recruiting	NCT02101775	Phase 2	Adavosertib;Gemcitabine Hydrochloride
18	Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer	Active, not recruiting	NCT01116648	Phase 1, Phase 2	Cediranib Maleate;Olaparib
19	Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers	Active, not recruiting	NCT00381641	Phase 2	Sunitinib;Sunitinib Malate
20	A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma	Active, not recruiting	NCT01723202	Phase 2	dabrafenib;trametinib
21	Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer	Active, not recruiting	NCT03630120	Phase 2	Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
22	Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer	Active, not recruiting	NCT01208051	Phase 1, Phase 2	Cediranib;Cediranib Maleate;Lenalidomide
23	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Suspended	NCT02978625	Phase 2
24	A Phase II Study of Atrasentan (ABT-627) Plus DOXIL in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Serous Papillary Adenocarcinoma Following Platinum + Taxane Therapy	Terminated	NCT00653328	Phase 2	atrasentan hydrochloride;doxil
25	A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors	Completed	NCT01100619	Phase 1	rosiglitazone;XL184
26	A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer	Completed	NCT00470496	Phase 1	HPPH;photodynamic therapy
27	A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake	Completed	NCT01413113	Phase 1	pazopanib hydrochloride
28	Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone	Completed	NCT01441154
29	Studies on Thyroid Nodules and Thyroid Cancer	Recruiting	NCT00001160
30	A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer	Withdrawn	NCT00053235

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Sources

Genetic Tests for Papillary Adenocarcinoma

Sources

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

⁴⁰

Thyroid, Breast, Lung, Cervix, Liver, Prostate, Pancreas

Sources

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 1364)

#	Title	Authors	PMID	Year
1	Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? ⁵⁴ ⁶¹	Moritani S...Kushima R	18339419	2008
2	Adult thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with thyroid transcription factor-1 expression. ⁵⁴ ⁶¹	Wu PY...Chien CY	17967658	2007
3	Case report of renal pelvic adenocarcinoma associated with a renal stone that produced carbohydrate antigen 125 and carbohydrate antigen 19-9. ⁵⁴ ⁶¹	Azumi M...Kakizaki H	17933139	2007
4	Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases. ⁵⁴ ⁶¹	Carrizo F...Luna MA	16084450	2005
5	Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. ⁵⁴ ⁶¹	Attanoos RL...Gibbs AR	11895489	2002
6	Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. ⁵⁴ ⁶¹	Kawamura T...Suzuki T	11505409	2001
7	[Expression of CD44V6 and nm23-H1 in thyroid papillary adenocarcinoma and lymph node metastasis]. ⁵⁴ ⁶¹	Wei Q...Fan S	10681781	1998
8	Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. ⁵⁴ ⁶¹	Podnos YD...Manetta A	9234924	1997
9	Cystic brain lesions: cytologic examination and carcinoembryonic antigen assay in fine needle aspirates. ⁵⁴ ⁶¹	Pinto MM	8629400	1996
10	[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test]. ⁵⁴ ⁶¹	Arao S...Funakoshi A	7474493	1995
11	Factors influencing growth rate of recurrent stomach cancers as determined by analysis of serum carcinoembryonic antigen. ⁵⁴ ⁶¹	Takahashi Y...Kusama S	7889481	1995
12	Small cell carcinoma of the stomach: an immunohistochemical and electron microscopic study. ⁵⁴ ⁶¹	Morikawa Y...Kakudo K	1333852	1992
13	Establishment of a human chorionic gonadotropin-producing human gastric carcinoma in nude mice. ⁵⁴ ⁶¹	Takahashi Y...Mai M	1921405	1991
14	Role of PET/CT in Management of Early Lung Adenocarcinoma. ⁶¹	Shao X...Wang Y	31714848	2020
15	Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma with Biphasic Histology. ⁶¹	Mirza R...Herrera GA	32015924	2020
16	Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ⁶¹	Baumann KB...Betz SJ	29995295	2019
17	Nasopharyngeal Papillary Adenocarcinoma as a Second Head and Neck Malignancy. ⁶¹	Kakkar A...Thakar A	29923095	2019
18	Frequent appearance of club cell (Clara cell)-like cells as a histological marker for ALK-positive lung adenocarcinoma. ⁶¹	Miyata-Morita K...Sawabe M	31625265	2019
19	Spontaneous pulmonary adenocarcinoma and subcutaneous cavernous hemangiomas arising in a squirrel monkey (Saimiri sciureus). ⁶¹	Salleng KJ...Himmel LE	31148179	2019
20	Clinicopathologic Characterization of Hidradenoma on Acral Sites: A Diagnostic Pitfall With Digital Papillary Adenocarcinoma. ⁶¹	Wiedemeyer K...Brenn T	31876586	2019
21	Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ⁶¹	Wang L...Yan D	31659975	2019
22	Endoscopic Low-Temperature Plasma Radiofrequency Ablation for Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ⁶¹	Zhong QY...Liu ZH	31619076	2019
23	Bone metastasis as a recurrence of early papillary adenocarcinoma of the stomach. ⁶¹	Agatsuma N...Yamashita Y	31606847	2019
24	[A Case of Resection for Bleeding from a Gallbladder Tumor]. ⁶¹	Ju M...Rino Y	31631164	2019
25	Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ⁶¹	Huang F...Li J	31287861	2019
26	Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. ⁶¹	Natale C...Krane LS	31395362	2019
27	Clinicopathologic Characteristics of Thyroid-like Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report. ⁶¹	Li L...Han C	29494399	2019
28	Trend and Characteristics of Endometrial Cancer in Lagos, Nigeria. ⁶¹	Okunowo AA...Anorlu RI	31591991	2019
29	Primary Ovarian Carcinoma with Rectal Metastasis-a Rare Presentation (a Case Report). ⁶¹	Kalita D...Pegu N	31496603	2019
30	Cardiac tamponade as an initial presentation of papillary carcinoma with psammoma bodies and intranuclear grooves-A diagnostic dilemma. ⁶¹	Gochhait D...Penumadu P	31120622	2019
31	Aggressive Digital Papillary Adenocarcinoma Initially Misdiagnosed as Basal Cell Carcinoma. ⁶¹	Chen ELA...Nijhawan RI	31567583	2019
32	Multiple primary lung adenocarcinomas pre-operatively diagnosed by discordant epidermal growth factor receptor mutations. ⁶¹	Katayama Y...Takemura Y	31139414	2019
33	[The effective mutation of epidermal growth factor receptor in synchronous multiple primary lung cancers: study of clinical, radiographic and pathological factors]. ⁶¹	Wang YJ...Zhao L	31434406	2019
34	Tumor Budding and Other Risk Factors of Lymph Node Metastasis in Submucosal Early Gastric Carcinoma: A Multicenter Clinicopathologic Study in 621 Radical Gastrectomies of Chinese Patients. ⁶¹	Du M...Huang Q	31094925	2019
35	Cytological differences between invasive and noninvasive or minimally invasive lung adenocarcinomas diagnosed in Japanese patients using needle biopsy specimens of pulmonary lesions ≤3 cm in diameter. ⁶¹	Matsubayashi J...Nagao T	30968597	2019
36	Nonthyroidal metastatic lesion in thyroid: A missed diagnosis and a lesson learnt. ⁶¹	Prameela CG...Sruthi K	31169237	2019
37	Efficacy and safety of endoscopic submucosal dissection for papillary adenocarcinoma-type early gastric cancer. ⁶¹	Park JH...Jeong HY	31232966	2019
38	[Nasopharyngeal low grade papillary adenocarcinoma with squamous differentiation：a case report]. ⁶¹	Ren XY...Zhang CF	31163537	2019
39	Thyroid-like low-grade papillary adenocarcinoma of nasopharynx. ⁶¹	Sourati A...Rakhshan A	31177192	2019
40	Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ⁶¹	Le QV...Ngo QX	31146581	2019
41	Genetic analysis of digital papillary adenocarcinoma. ⁶¹	Nishida H	31025737	2019
42	Low-grade papillary adenocarcinoma of nasopharynx. Case report and review of the literature. ⁶¹	Garcia-Gomez J...Fernandez-Rodriguez G	30075860	2019
43	Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. ⁶¹	Surowy HM...Redler S	30472730	2019
44	A Case of Endoscopic Mucosal Resection of Carcinoma in Adenoma at the Minor Duodenal Papilla. ⁶¹	Kawashima Y...Mine T	31182951	2019
45	Polypoid gallbladder tumors with a deep hypoechoic area and a conically thickened outermost hyperechoic layer suggest shallow T2 carcinoma. ⁶¹	Fujimoto T...Kato Y	31205753	2019
46	A case of lung adenocarcinoma complicated by pulmonary talcosis occurring in a patient employed in the confectionery industry. ⁶¹	Kobayashi K...Miyazaki T	30775827	2019
47	The Risk of Misdiagnosing Pulmonary Adenocarcinoma as Traumatic Pseudocyst in a Young Adult. ⁶¹	Kamiyoshihara M...Yazawa T	30315800	2019
48	An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report. ⁶¹	Takeda M...Nakayama K	31030664	2019
49	[Digital papillary adenocarcinoma : Four case reports with brief literature review]. ⁶¹	Held L...Rutten A	30478600	2019
50	Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. ⁶¹	Kim TS...Kim JJ	30039320	2019

Sources

Genes for Papillary Adenocarcinoma

Genes related to Papillary Adenocarcinoma (0 elite genes):

(show all 26)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	NKX2-1	NK2 Homeobox 1	Protein Coding	21.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17967658 16084450
2	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	20.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11895489 8629400 1327687 (more) 7889481
3	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	19.62	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1333852 12498221
4	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	19.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	18339419 9234924 17933139
5	KRT7	Keratin 7	Protein Coding	13.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	13.54	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
7	TP53	Tumor Protein P53	Protein Coding	13.21	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	13.1	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	12.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	PGR	Progesterone Receptor	Protein Coding	12.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	KRT19	Keratin 19	Protein Coding	11.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CDH1	Cadherin 1	Protein Coding	11.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	PIP	Prolactin Induced Protein	Protein Coding	11.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	VIM	Vimentin	Protein Coding	10.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	CDH2	Cadherin 2	Protein Coding	10.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	KEAP1	Kelch Like ECH Associated Protein 1	Protein Coding	10.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	NFE2L2	Nuclear Factor, Erythroid 2 Like 2	Protein Coding	9.65	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	MIR141	MicroRNA 141	RNA Gene	8	DISEASES inferred ¹⁵ ¹⁵
19	MIR30A	MicroRNA 30a	RNA Gene	7.93	DISEASES inferred ¹⁵ ¹⁵
20	MST1R	Macrophage Stimulating 1 Receptor	Protein Coding	7.65	GeneCards inferred via : Disorders (show sections)
21	MIR30E	MicroRNA 30e	RNA Gene	7.52	DISEASES inferred ¹⁵ ¹⁵
22	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	7.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	10681781
23	MIR21	MicroRNA 21	RNA Gene	7.13	DISEASES inferred ¹⁵ ¹⁵
24	SLC2A1	Solute Carrier Family 2 Member 1	Protein Coding	6.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11505409
25	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.69	DISEASES inferred ¹⁵
26	CEACAM3	CEA Cell Adhesion Molecule 3	Protein Coding	6.68	GeneCards inferred via : Publications (show sections)

Sources

Variations for Papillary Adenocarcinoma

Sources

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Sources

Pathways for Papillary Adenocarcinoma

Pathways related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.66	VIM TP53 PIP MUC1 MST1R ERBB2
2	Pathways in cancer ³⁶	12.52	TP53 NFE2L2 KEAP1 ERBB2 CDH1 BRCA2
3	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.47	TP53 ERBB2 CDH1 BRCA2 BRCA1
4	Development ERBB-family signaling ²² Show member pathways Development EGFR signaling pathway ²² EGF Pathway ⁶³ EGFR Signaling Pathway ⁶⁶ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶⁵ PLCG1 events in ERBB2 signaling ⁶⁵	12.35	TP53 MUC1 ERBB2 CDH1
5	Cytoskeletal Signaling ⁴	12.32	VIM MUC1 KRT7 KRT19 CDH1
6	Integrated Breast Cancer Pathway ¹	11.95	TP53 CDH1 BRCA2 BRCA1
7	MicroRNAs in cancer ³⁶	11.92	VIM TP53 MIR30A MIR141 ERBB2 BRCA1
8	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	11.89	TP53 PGR NFE2L2 KEAP1 ERBB2 CDH1
9	Adhesion ⁴	11.76	MUC1 CEACAM5 CDH2 CDH1
10	BRCA1 Pathway ⁶³ Show member pathways Fanconi's Anaemia Pathway ⁶³	11.65	TP53 BRCA2 BRCA1
11	Platinum drug resistance ³⁶	11.56	TP53 ERBB2 BRCA1
12	Bladder cancer ³⁶ ¹	11.55	TP53 ERBB2 CDH1
13	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.49	TP53 ERBB2 BRCA1
14	a6b1 and a6b4 Integrin signaling ¹	10.92	MST1R ERBB2 CDH1
15	G-protein signaling_Rap2B regulation pathway ²²	10.78	VIM PIP MST1R ERBB2 CDH2 CDH1
16	TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition ¹	10.59	VIM CDH2 CDH1

Sources

GO Terms for Papillary Adenocarcinoma

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.85	TP53 NKX2-1 NFE2L2 CDH1 BRCA2 BRCA1
2	viral process	GO:0016032	9.73	VIM TP53 NFE2L2 KRT7 KRT19 KEAP1
3	double-strand break repair	GO:0006302	9.63	TP53 BRCA2 BRCA1
4	positive regulation of gene expression	GO:0010628	9.56	VIM TP53 PIP NKX2-1 NFE2L2 MIR30A
5	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.43	TP53 NFE2L2
6	cellular response to indole-3-methanol	GO:0071681	9.4	CDH1 BRCA1
7	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.33	TP53 NFE2L2 MUC1
8	chordate embryonic development	GO:0043009	9.32	BRCA2 BRCA1
9	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	8.92	TP53 MUC1 BRCA2 BRCA1

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription regulatory region DNA binding	GO:0044212	9.56	TP53 NKX2-1 NFE2L2 BRCA1
2	protein phosphatase binding	GO:0019903	9.5	TP53 ERBB2 CDH2
3	enzyme binding	GO:0019899	9.43	TP53 PGR NKX2-1 MST1R CDH2 BRCA1
4	identical protein binding	GO:0042802	9.32	VIM TP53 PGR KEAP1 ERBB2 CEACAM5
5	transcription cofactor binding	GO:0001221	9.16	TP53 NFE2L2

Sources

Sources for Papillary Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia